[Form 3] MIRA PHARMACEUTICALS, INC. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

MIRA Pharmaceuticals filed a Form 3 reporting initial beneficial ownership following a transaction dated 09/29/2025 involving Telomir Pharmaceuticals, Inc. (TELO). The filing shows the reporting person is identified as a director and discloses ownership of 3,521,127 shares of the issuer's common stock, no par value. The shares were acquired in connection with the reporting person’s acquisition of SKNY Pharmaceuticals, Inc. The Form 3 is signed by Erez Aminov, CEO on 10/03/2025.

Positive

• 3,521,127 shares disclosed as beneficially owned, providing clear transparency
• Ownership origin is specified: acquired in connection with the SKNY Pharmaceuticals, Inc. acquisition

Negative

• None.

Insights

Corporate Governance Analyst

Form 3 records a director-level insider now holding 3,521,127 shares.

The filing formalizes insider ownership after a corporate transaction and notifies the market that a company insider holds a substantial equity stake in TELO. Reporting on a Form 3 is required when an officer/director/10% owner first becomes a beneficial owner; here it documents initial ownership of 3,521,127 shares.

This disclosure allows investors and regulators to track insider holdings and potential related-party dynamics tied to the disclosed acquisition.

M&A Transaction Analyst

The share position arose from an acquisition of SKNY Pharmaceuticals, Inc.

The filing explicitly states the 3,521,127 shares were acquired in connection with the reporting person’s acquisition of SKNY Pharmaceuticals, Inc. That links the insider stake directly to an M&A consideration or post-closing ownership allocation.

This ties the insider’s equity position to a specific corporate transaction, clarifying the origin of the shares disclosed in the Form 3.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

MIRA PHARMACEUTICALS, INC.

(Last) (First) (Middle)

1200 BRICKELL AVE. SUITE 1950 #1183

(Street)

MIAMI FL 33131

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/29/2025

3. Issuer Name and Ticker or Trading Symbol
Telomir Pharmaceuticals, Inc. [ TELO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, no par value(1)	3,521,127	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents 3,521,127 shares of the Issuer's common stock, no par value, acquired in connection with the Reporting Person's acquisition of SKNY Pharmaceuticals, Inc.

	/s/ Erez Aminov, CEO	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MIRA disclose in the Form 3 filing?

The Form 3 discloses beneficial ownership of 3,521,127 shares of common stock and states the shares were acquired in connection with the acquisition of SKNY Pharmaceuticals, Inc.

Which issuer and ticker are referenced in the filing?

The filing references Telomir Pharmaceuticals, Inc. with the trading symbol TELO.

When was the event requiring this Form 3 recorded?

The Date of Event requiring the statement is listed as 09/29/2025.

Who signed the Form 3 and when?

The Form 3 is signed by Erez Aminov, CEO with a signature date of 10/03/2025.

What is the reporting person’s role relative to the issuer?

The filing indicates the reporting person is a director of the issuer.